Formulation and Evaluation of Orodispersible Tablets of Galantamine Hydrochloride for Effective Treatment of Alzheimer

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. Alzheimer’s disease is commonly managed using cholinesterase inhibitors such as Galantamine Hydrochloride, which enhances cholinergic transmission in the brain by inhibiting acetylcholinesterase enzyme activity.
The present study was aimed at the formulation and evaluation of Orodispersible Tablets (ODTs) of Galantamine Hydrochloride to improve patient compliance, particularly in geriatric patients who experience difficulty in swallowing conventional tablets. ODTs were prepared by direct compression method using suitable superdisintegrants and excipients. Pre-compression parameters such as angle of repose, bulk density, tapped density, Carr’s index, and Hausner ratio were evaluated to assess flow properties of the powder blend.
Post-compression evaluation included hardness, thickness, weight variation, friability, disintegration time, wetting time, drug content, and in-vitro dissolution studies. All formulated batches complied with pharmacopoeial limits. The optimized batch showed acceptable mechanical strength, rapid disintegration, and satisfactory drug release profile.
The results indicated that the developed Orodispersible Tablets of Galantamine Hydrochloride can provide rapid onset of action and improved patient convenience, making them a promising alternative to conventional dosage forms for the effective management of Alzheimer’s disease.

Galantamine Hydrochloride , Alzheimer’s disease, Orodispersible Tablets (ODT)Direct Compression, Superdisintegrants ,In-vitro Dissolution Study, Drug Release Kinetics Patient Compliance